# US 2016/0257942 A1 · Modified helicases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257942 A1
- Document ID: US20160257942A1
- Status: Published application
- Kind: A1
- Application number: 15/028,651
- Filed: 2014-09-10
- Published: 2016-09-08
- Earliest claimed: 2013-10-18
- Assignees: Oxford Nanopore Technologies PLC
- Applicants: Oxford Nanopore Technologies Limited
- Inventors: Mark Bruce; Andrew John Heron; Ruth Moysey; Szabolcs Soeroes; Elizabeth Jayne Wallace; James White
- Web page: https://patentgrep.com/patent/US20160257942A1

## CPC

- C12N 9/14: Hydrolases (3)
- C12N 9/90: Isomerases (5.)
- C12Q 1/6869: Methods for sequencing
- C12Q 2565/631: being a biochannel or pore
- C12Y 306/04012: DNA helicase (3.6.4.12)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES

## Abstract

The invention relates to a new method of characterising a target polynucleotide. The method uses a pore and a Dda helicase. The helicase controls the movement of the target polynucleotide through the pore. The invention also relates to modified Dda helicases which can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.

## Claims

### Claim 1

A DNA-dependent ATPase (Dda) helicase in which at least one cysteine residue and/or at least one non-natural amino acid have been introduced into (i) the tower domain and/or (ii) the pin domain and/or (iii) the 1A (RecA-like motor) domain, wherein the helicase retains its ability to control the movement of a polynucleotide.

### Claim 2 (depends on 1)

A helicase according to claim 1, wherein:
(A) the helicase comprises:
(a) a variant of SEQ ID NO: 8 in which at least one cysteine residue and/or at least one non-natural amino acid have been introduced into (i) the tower domain (residues D260-P274 and N292-A389) and/or (ii) the pin domain (residues K86-E102) and/or the (iii) 1A domain (residues M1-L85 and V103-K177);
(b) a variant of SEQ ID NO: 9 in which at least one cysteine residue and/or at least one non-natural amino acid have been introduced into (i) the tower domain (residues G295-N309 and F316-Y421) and/or (ii) the pin domain (Y85-L112) and/or the (iii) 1A domain (residues M1-184 and R113-Y211);
(c) a variant of SEQ ID NO: 10 in which at least one cysteine residue and/or at least one non-natural amino acid have been introduced into (i) the tower domain (residues V328-P342 and N360-Y448) and/or (ii) the pin domain (residues K148-N165) and/or the (iii) 1A domain (residues M1-L147 and 5166-V240);
(d) a variant of SEQ ID NO: 11 in which at least one cysteine residue and/or at least one non-natural amino acid have been introduced into (i) the tower domain (residues A261-T275 and T285-Y370) and/or (ii) the pin domain (residues G91-E107) and/or the (iii) 1A domain (residues M1-L90 and E108-H173);
(e) a variant of SEQ ID NO: 12 in which at least one cysteine residue and/or at least one non-natural amino acid have been introduced into (i) the tower domain (residues G294-I307 and T314-Y407) and/or (ii) the pin domain (residues G116-T135) and/or the (iii) 1A domain (residues M1-L115 and N136-V205);
(f) a variant of SEQ ID NO: 13 in which at least one cysteine residue and/or at least one non-natural amino acid have been introduced into (i) the tower domain (residues V288-E301 and N307-N393) and/or (ii) the pin domain (residues G97-P113) and/or the (iii) 1A domain (residues M1-L96 and F114-V194);
(g) a variant of SEQ ID NO: 14 in which at least one cysteine residue and/or at least one non-natural amino acid have been introduced into (i) the tower domain (residues 5250-P264 and E278-S371) and/or (ii) the pin domain (residues K78-E95) and/or the (iii) 1A domain (residues M1-L77 and V96-V166);
(h) a variant of SEQ ID NO: 15 in which at least one cysteine residue and/or at least one non-natural amino acid have been introduced into (i) the tower domain (residues K255-P269 and T284-5380) and/or (ii) the pin domain (residues K82-K98) and/or the (iii) 1A domain (residues M1-M81 and L99-M171);
(i) a variant of SEQ ID NO: 16 in which at least one cysteine residue and/or at least one non-natural amino acid have been introduced into (i) the tower domain (residues D242-P256 and T271-S366) and/or (ii) the pin domain (residues K69-K85) and/or the (iii) 1A domain (residues M1-M68 and M86-M158);
(j) a variant of SEQ ID NO: 17 in which at least one cysteine residue and/or at least one non-natural amino acid have been introduced into (i) the tower domain (residues T263-P277 and N295-P392) and/or (ii) the pin domain (residues K88-K107) and/or the (iii) 1A domain (residues M1-L87 and A108-M181);
(k) a variant of SEQ ID NO: 18 in which at least one cysteine residue and/or at least one non-natural amino acid have been introduced into (i) the tower domain (residues D263-P277 and N295-A391) and/or (ii) the pin domain (residues K88-K107) and/or the (iii) 1A domain (residues M1-L87 and A108-M181);
(l) a variant of SEQ ID NO: 19 in which at least one cysteine residue and/or at least one non-natural amino acid have been introduced into (i) the tower domain (residues A258-P272 and N290-P386) and/or (ii) the pin domain (residues K86-G102) and/or the (iii) 1A domain (residues M1-L85 and T103-K176);
(m) a variant of SEQ ID NO: 20 in which at least one cysteine residue and/or at least one non-natural amino acid have been introduced into (i) the tower domain (residues L266-P280 and N298-A392) and/or (ii) the pin domain (residues K92-D108) and/or the (iii) 1A domain (residues M1-L91 and V109-M183);
(n) a variant of SEQ ID NO: 21 in which at least one cysteine residue and/or at least one non-natural amino acid have been introduced into (i) the tower domain (residues D262-P276 and N294-A392) and/or (ii) the pin domain (residues K88-E104) and/or the (iii) 1A domain (residues M1-L87 and M105-M179);
(o) a variant of SEQ ID NO: 22 in which at least one cysteine residue and/or at least one non-natural amino acid have been introduced into (i) the tower domain (residues D261-P275 and N293-A389) and/or (ii) the pin domain (residues K87-E103) and/or the (iii) 1A domain (residues M1-L86 and V104-K178); or
(p) a variant of SEQ ID NO: 23 in which at least one cysteine residue and/or at least one non-natural amino acid have been introduced into (i) the tower domain (residues E261-P275 and T293-A390) and/or (ii) the pin domain (residues K87-E103) and/or the (iii) 1A domain (residues M1-L86 and V104-M178); or
(B) the helicase further comprises:
(i) one or more single amino acid deletions from the pin domain and/or the hook domain;
(ii) one or more single amino acid deletions from the pin domain and/or the hook domain, and a variant of SEQ ID NO: 8 which comprises deletion of E93 and/or deletion of E95; or
(iii) one or more single amino acid deletions from the pin domain and/or the hook domain, and a variant of any one of SEQ ID NOs: 9 to 23 which comprises deletion of the position corresponding to E93 in SEQ ID NO: 8 and/or deletion of the position corresponding to E95 in SEQ ID NO: 8; or
(C) at least one cysteine residue and/or at least one non-natural amino acid have been further introduced into the hook domain and/or the 2A (RecA-like) domain; or
(D) the helicase comprises:
(a) a variant of SEQ ID NO: 8 in which at least one cysteine residue and/or at least one non-natural amino acid have further been introduced into the hook domain (residues L275-F291) and/or the 2A (RecA-like) domain (residues R178-T259 and L390-V439);
(b) a variant of SEQ ID NO: 9 in which at least one cysteine residue and/or at least one non-natural amino acid have further been introduced into the hook domain (residues A310-L315) and/or the 2A (RecA-like) domain (residues R212-E294 and G422-S678);
(c) a variant of SEQ ID NO: 10 in which at least one cysteine residue and/or at least one non-natural amino acid have further been introduced into the hook domain (residues V343-L359) and/or the 2A (RecA-like) domain (residues R241-N327 and A449-G496);
(d) a variant of SEQ ID NO: 11 in which at least one cysteine residue and/or at least one non-natural amino acid have further been introduced into the hook domain (residues W276-L284) and/or the 2A (RecA-like) domain (residues R174-D260 and A371-V421);
(e) a variant of SEQ ID NO: 12 in which at least one cysteine residue and/or at least one non-natural amino acid have further been introduced into the hook domain (residues R308-Y313) and/or the 2A (RecA-like) domain (residues R206-K293 and I408-L500);
(f) a variant of SEQ ID NO: 13 in which at least one cysteine residue and/or at least one non-natural amino acid have further been introduced into the hook domain (residues M302-W306) and/or the 2A (RecA-like) domain (residues R195-D287 and V394-Q450);
(g) a variant of SEQ ID NO: 14 in which at least one cysteine residue and/or at least one non-natural amino acid have further been introduced into the hook domain (residues V265-I277) and/or the 2A (RecA-like) domain (residues R167-T249 and L372-N421);
(h) a variant of SEQ ID NO: 15 in which at least one cysteine residue and/or at least one non-natural amino acid have further been introduced into the hook domain (residues V270-F283) and/or the 2A (RecA-like) domain (residues R172-T254 and L381-K434);
(i) a variant of SEQ ID NO: 16 in which at least one cysteine residue and/or at least one non-natural amino acid have further been introduced into the hook domain (residues V257-F270) and/or the 2A (RecA-like) domain (residues R159-T241 and L367-K420);
(j) a variant of SEQ ID NO: 17 in which at least one cysteine residue and/or at least one non-natural amino acid have further been introduced into the hook domain (residues L278-Y294) and/or the 2A (RecA-like) domain (residues R182-T262 and L393-V443);
(k) a variant of SEQ ID NO: 18 in which at least one cysteine residue and/or at least one non-natural amino acid have further been introduced into the hook domain (residues L278-Y294) and/or the 2A (RecA-like) domain (residues R182-T262 and L392-V442);
(l) a variant of SEQ ID NO: 19 in which at least one cysteine residue and/or at least one non-natural amino acid have further been introduced into the hook domain (residues L273-F289) and/or the 2A (RecA-like) domain (residues R177-N257 and L387-V438);
(m) a variant of SEQ ID NO: 20 in which at least one cysteine residue and/or at least one non-natural amino acid have further been introduced into the hook domain (residues L281-F297) and/or the 2A (RecA-like) domain (residues R184-T265 and L393-I442);
(n) a variant of SEQ ID NO: 21 in which at least one cysteine residue and/or at least one non-natural amino acid have further been introduced into the hook domain (residues H277-F293) and/or the 2A (RecA-like) domain (residues R180-T261 and L393-V442);
(o) a variant of SEQ ID NO: 22 in which at least one cysteine residue and/or at least one non-natural amino acid have further been introduced into the hook domain (residues L276-F292) and/or the 2A (RecA-like) domain (residues R179-T260 and L390-I439); or
(p) a variant of SEQ ID NO: 23 in which at least one cysteine residue and/or at least one non-natural amino acid have further been introduced into the hook domain (residues L276-F292) and/or the 2A (RecA-like) domain (residues R179-T260 and L391-V441); or
(E) the helicase is further modified to reduce its surface negative charge; or
(F) the helicase is further modified by the removal of one or more native cysteine residues; or
(G) at least one cysteine residue and/or at least one non-natural amino acid have been introduced into the tower domain only, wherein the helicase retains its ability to control the movement of a polynucleotide; or
(H) the at least one non-natural amino acids is selected from 4-Azido-L-phenylalanine (Faz), 4-Acetyl-L-phenylalanine, 3-Acetyl-L-phenylalanine, 4-Acetoacetyl-L-phenylalanine, O-Allyl-L-tyrosine, 3-(Phenylselanyl)-L-alanine, O-2-Propyn-1-yl-L-tyrosine, 4-(Dihydroxyboryl)-L-phenylalanine, 4-[(Ethylsulfanyl)carbonyl]-L-phenylalanine, (2S)-2-amino-3-{4-[(propan-2-ylsulfanyl)carbonyl]phenyl}propanoic acid, (2S)-2-amino-3-{4-[(2-amino-3-sulfanylpropanoyl)amino]phenyl}propanoic acid, O-Methyl-L-tyrosine, 4-Amino-L-phenylalanine, 4-Cyano-L-phenylalanine, 3-Cyano-L-phenylalanine, 4-Fluoro-L-phenylalanine, 4-Iodo-L-phenylalanine, 4-Bromo-L-phenylalanine, O-(Trifluoromethyl)tyrosine, 4-Nitro-L-phenylalanine, 3-Hydroxy-L-tyrosine, 3-Amino-L-tyrosine, 3-Iodo-L-tyrosine, 4-Isopropyl-L-phenylalanine, 3-(2-Naphthyl)-L-alanine, 4-Phenyl-L-phenylalanine, (2S)-2-amino-3-(naphthalen-2-ylamino)propanoic acid, 6-(Methylsulfanyl)norleucine, 6-Oxo-L-lysine, D-tyrosine, (2R)-2-Hydroxy-3-(4-hydroxyphenyl)propanoic acid, (2R)-2-Ammoniooctanoate3-(2,2′-Bipyridin-5-yl)-D-alanine, 2-amino-3-(8-hydroxy-3-quinolyl)propanoic acid, 4-Benzoyl-L-phenylalanine, S-(2-Nitrobenzyl)cysteine, (2R)-2-amino-3-[(2-nitrobenzyl)sulfanyl]propanoic acid, (2S)-2-amino-3-[(2-nitrobenzyl)oxy]propanoic acid, O-(4,5-Dimethoxy-2-nitrobenzyl)-L-serine, (2S)-2-amino-6-({[(2-nitrobenzyl)oxy]carbonyl}amino)hexanoic acid, O-(2-Nitrobenzyl)-L-tyrosine, 2-Nitrophenylalanine, 4-[(E)-Phenyldiazenyl]-L-phenylalanine, 4-[3-(Trifluoromethyl)-3H-diaziren-3-yl]-D-phenylalanine, 2-amino-3-[[5-(dimethylamino)-1-naphthyl]sulfonylamino]propanoic acid, (2S)-2-amino-4-(7-hydroxy-2-oxo-2H-chromen-4-yl)butanoic acid, (2S)-3-[(6-acetylnaphthalen-2-yl)amino]-2-aminopropanoic acid, 4-(Carboxymethyl)phenylalanine, 3-Nitro-L-tyrosine, O-Sulfo-L-tyrosine, (2R)-6-Acetamido-2-ammoniohexanoate, 1-Methylhistidine, 2-Aminononanoic acid, 2-Aminodecanoic acid, L-Homocysteine, 5-Sulfanylnorvaline, 6-Sulfanyl-L-norleucine, 5-(Methylsulfanyl)-L-norvaline, N6-{[R2R,3R)-3-Methyl-3,4-dihydro-2H-pyrrol-2-yl]carbonyl}-L-lysine, N6-[(Benzyloxy)carbonyl]lysine, (2S)-2-amino-6-[(cyclopentylcarbonyl)amino]hexanoic acid, N6-[(Cyclopentyloxy)carbonyl]-L-lysine, (2S)-2-amino-6-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}hexanoic acid, (2S)-2-amino-8-[(2R,3S)-3-ethynyltetrahydrofuran-2-yl]-8-oxooctanoic acid, N6-(tert-Butoxycarbonyl)-L-lysine, (2S)-2-Hydroxy-6-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)hexanoic acid, N6-[(Allyloxy)carbonyl]lysine, (2S)-2-amino-6-({[R2-azidobenzyl)oxy]carbonyl}amino)hexanoic acid, N6-L-Prolyl-L-lysine, (2S)-2-amino-6-{[(prop-2-yn-1-yloxy)carbonyl]amino}hexanoic acid and N6-[(2-Azidoethoxy)carbonyl]-L-lysine.

### Claim 3 (depends on 2)

A helicase according to claim 2, wherein the helicase comprises:
(a) a variant of SEQ ID NO: 8 which comprises (i) E94C and/or A360C; (ii) E93C and/or K358C; (iii) E93C and/or A360C; (iv) E93C and/or E361C; (v) E93C and/or K364C; (vi) E94C and/or L354C; (vii) E94C and/or K358C; (viii) E93C and/or L354C; (ix) E94C and/or E361C; (x) E94C and/or K364C; (xi) L97C and/or L354C; (xii) L97C and/or K358C; (xiii) L97C and/or A360C; (xiv) L97C and/or E361C; (xv) L97C and/or K364C; (xvi) K123C and/or L354C; (xvii) K123C and/or K358C; (xviii) K123C and/or A360C; (xix) K123C and/or E361C; (xx) K123C and/or K364C; (xxi) N155C and/or L354C; (xxii) N155C and/or K358C; (xxiii) N155C and/or A360C; (xxiv) N155C and/or E361C; (xxv) N155C and/or K364C; (xxvi) any of (i) to (xxv) and G357C; (xxvii) any of (i) to (xxv) and Q100C; (xxviii) any of (i) to (xxv) and I127C; (xxix) any of (i) to (xxv) and Q100C and I127C; (xxx) E94C and/or F377C; (xxxi) N95C; (xxxii) T91C; (xxxiii) Y92L, E94Y, Y350N, A360C and Y363N; (xxxiv) E94Y and A360C; (xxxv) A360C; (xxxvi) Y92L, E94C, Y350N, A360Y and Y363N; (xxxvii) Y92L, E94C and A360Y; (xxxviii) E94C and/or A360C and F276A; (xxxix) E94C and/or L356C; (xl) E93C and/or E356C; (xli) E93C and/or G357C; (xlii) E93C and/or A360C; (xliii) N95C and/or W378C; (xliv) T91C and/or S382C; (xlv) T91C and/or W378C; (xlvi) E93C and/or N353C; (xlvii) E93C and/or S382C; (xlviii) E93C and/or K381C; (xlix) E93C and/or D379C; (1) E93C and/or S375C; (ii) E93C and/or W378C; (lii) E93C and/or W374C; (liii) E94C and/or N353C; (liv) E94C and/or S382C; (iv) E94C and/or K381C; (lvi) E94C and/or D379C; (lvii) E94C and/or S375C; (lviii) E94C and/or W378C; (lix) E94C and/or W374C; (lx) E94C and A360Y; (lxi) E94C, G357C and A360C or (lxii) T2C, E94C and A360C; or
(b) a variant of any one of SEQ ID NOs: 9 to 23 which comprises a cysteine residue at the positions which correspond to those in SEQ ID NO: 8 in any of (i) to (xxix); or
(c) a variant of SEQ ID NO:8 which comprises any of (i) to (xxix), wherein 4-Azido-L-phenylalanine (Faz) is introduced at one or more of the specific positions instead of cysteine; or
(d) a variant of any one of SEQ ID NOs: 9 to 23 which comprises a 4-Azido-L-phenylalanine (Faz) residue at the positions which correspond to those in SEQ ID NO: 8 in any of (i) to (xxix).

### Claim at position 4

-8. (canceled)

### Claim 9 (depends on 2)

A helicase according to claim 2, wherein the helicase comprises:
(a) a variant of SEQ ID NO: 8 which comprises one or more of (i) I181C; (ii) Y279C; (iii) I281C; and (iv) E288C; or
(b) a variant of any one of SEQ ID NOs: 9 to 23 which comprises a cysteine residue at one or more of the position(s) which correspond to those in SEQ ID NO: 8 as defined in (i) to (iv); or
(c) a variant of SEQ ID NO: 8 which comprises one or more of (i) to (iv), wherein Faz is introduced at one or more of the specific positions instead of cysteine; or
(d) a variant of any one of SEQ ID NOs: 9 to 23 which comprises a Faz residue at one or more of the position(s) which correspond to those in SEQ ID NO: 8 as defined in (i) to (iv).

### Claim at position 6

-11. (canceled)

### Claim 12 (depends on 2)

A helicase according to claim 2, wherein:
(a) one or more surface negative charges have been neutralised by substituting one or more negatively charged amino acids with one or more positively charged amino acids, uncharged amino acids, non-polar amino acids and/or aromatic amino acids or by introducing one or more positively charged amino acids adjacent to one or more negatively charged amino acids; and/or
(b) the helicase comprises a variant of SEQ ID NO: 8 and the one or more negatively charged amino acids are one or more of D5, E8, E23, E47, D167, E172, D202 and D212.

### Claim at position 8

-14. (canceled)

### Claim 15 (depends on 2)

A helicase according to claim 2, wherein:
(a) the one or more cysteine residues are removed by substitution,
(b) the one or more cysteine residues are removed by substitution and the one or more cysteine residues are substituted with alanine, serine or valine; or
(c) the helicase comprises:
(a) a variant of SEQ ID NO: 8 and the one or more native cysteine residues are one or more of C109, C114, C136, C171 and C412;
(b) a variant of any one of SEQ ID NOs: 9 to 23 and the one or more native cysteine residues correspond to one or more of C109, C114, C136, C171 and C412 in SEQ ID NO: 8.

### Claim at position 10

-18. (canceled)

### Claim 19 (depends on 2)

A helicase according to claim 2, wherein the helicase comprises any of the tower domain variants defined in claim 2.

### Claim 20 (depends on 2)

A Dda helicase in which:
(a) at least one cysteine residue and/or at least one non-natural amino acid have been introduced into the hook domain and/or the 2A (RecA-like motor) domain, wherein the helicase retains its ability to control the movement of a polynucleotide; or
(b) at least one cysteine residue and/or at least one non-natural amino acid have been introduced into the hook domain and/or the 2A (RecA-like motor) domain, wherein the helicase retains its ability to control the movement of a polynucleotide and wherein the helicase comprises any of the variants defined in claim 2 or the mutations defined in claim 2.

### Claim at position 13

-22. (canceled)

### Claim 23 (depends on 12)

A Dda helicase which is modified to reduce its surface negative charge,
wherein:
(a) the helicase retains its ability to control the movement of a polynucleotide; or
(b) the helicase retains its ability to control the movement of a polynucleotide and the helicase is modified as defined in (a) of claim 12.

### Claim 24

(canceled)

### Claim 25 (depends on 2)

A polypeptide comprising:
(a) the pin domain and the 1A (RecA-like motor) domain from a Dda helicase and not comprising any other domains from a Dda helicase, wherein at least one cysteine residue and/or at least one non-natural amino acid have been introduced into the pin domain and/or the 1A (RecA-like motor) domain; or
(b) the pin domain and the 1A (RecA-like motor) domain from a Dda helicase and not comprising any other domains from a Dda helicase, wherein at least one cysteine residue and/or at least one non-natural amino acid have been introduced into the pin domain and/or the 1A (RecA-like motor) domain and wherein the polypeptide comprises any of the variants of the pin domains and the 1A (RecA-like motor) domains defined in claim 2 and any of the pin domain and/or 1A domain mutations; or
(c) the 2A (RecA-like motor) domain, tower domain and hook domain from a Dda helicase and not comprising any other domains from a Dda helicase, wherein at least one cysteine residue and/or at least one non-natural amino acid have been introduced into the tower domain; or
(d) the 2A (RecA-like motor) domain, tower domain and hook domain from a Dda helicase and not comprising any other domains from a Dda helicase, wherein at least one cysteine residue and/or at least one non-natural amino acid have been introduced into the tower domain and wherein the polypeptide comprises a variant of the tower domains or a tower domain mutation.

### Claim at position 17

-28. (canceled)

### Claim 29 (depends on 25)

A helicase comprising a polypeptide according to claim 25 covalently attached to a polypeptide, wherein the helicase has the ability to control the movement of a polynucleotide.

### Claim 30 (depends on 1)

A helicase according to claim 1,
wherein:
(a) two more of the introduced cysteines and/or non-natural amino acids are connected to one another; or
(b) none of the introduced cysteines and/or non-natural amino acids are connected to one another.

### Claim 31

(canceled)

### Claim 32 (depends on 1)

A construct comprising a Dda helicase or a helicase according claim 1 and an additional polynucleotide binding moiety,
wherein:
(a) the helicase is attached to the polynucleotide binding moiety and the construct has the ability to control the movement of a polynucleotide; or
(b) the helicase is attached to the polynucleotide binding moiety, the construct has the ability to control the movement of a polynucleotide, and the construct comprises two or more helicases according to claim 1.

### Claim 33

(canceled)

### Claim 34 (depends on 1)

A polynucleotide which comprises a sequence which encodes a helicase according to claim 1, a polypeptide or a construct.

### Claim 35 (depends on 34)

A vector which comprises a polynucleotide according to claim 34 operably linked to a promoter.

### Claim 36 (depends on 35)

A host cell comprising a vector according to claim 35.

### Claim 37 (depends on 34)

A method of making a helicase, a polypeptide or a construct, which comprises expressing a polynucleotide according to claim 34, transfecting a cell with a vector comprising the polynucleotide or culturing a host cell comprising the polynucleotide.

### Claim 38 (depends on 32)

A method of controlling the movement of a polynucleotide, comprising contacting the polynucleotide with a Dda helicase or a construct according to claim 32 and thereby controlling the movement of the polynucleotide.

### Claim 39 (depends on 38)

A method according to claim 38, wherein the method is for controlling the movement of a polynucleotide through a transmembrane pore.

### Claim 40 (depends on 32)

A method of characterising a target polynucleotide, comprising:
(a) contacting the target polynucleotide with a transmembrane pore and a Dda helicase or a construct according to claim 32 such that the helicase controls the movement of the target polynucleotide through the pore; and
(b) taking one or more measurements as the polynucleotide moves with respect to the pore wherein the measurements are indicative of one or more characteristics of the target polynucleotide and thereby characterising the target polynucleotide.

### Claim 41 (depends on 1)

A method comprising contacting the polynucleotide with a Dda helicase, wherein:
(a) the Dda helicase is a helicase according to claim 1; or
(b) the Dda helicase is a helicase according to claim 1, and wherein one or more characteristics of the polynucleotide are determined, wherein the one or more characteristics are selected from (i) the length of the target polynucleotide, (ii) the identity of the target polynucleotide, (iii) the sequence of the target polynucleotide, (iv) the secondary structure of the target polynucleotide and (v) whether or not the target polynucleotide is modified; or
(c) the Dda helicase is a helicase according to claim 1; wherein one or more characteristics of the polynucleotide are determined, wherein the one or more characteristics are selected from (i) the length of the target polynucleotide, (ii) the identity of the target polynucleotide, (iii) the sequence of the target polynucleotide, (iv) the secondary structure of the target polynucleotide and (v) whether or not the target polynucleotide is modified; and wherein the target polynucleotide is modified by methylation, by oxidation, by damage, with one or more proteins or with one or more labels, tags or spacers.

### Claim at position 31

-43. (canceled)

### Claim 44 (depends on 40)

A method according to claim 40, wherein:
(A) the one or more characteristics of the target polynucleotide are measured by electrical measurement and/or optical measurement; and/or
(B) (i) the one or more characteristics of the target polynucleotide are measured by an electrical measurement, wherein the electrical measurement is a current measurement, an impedance measurement, a tunnelling measurement or a field effect transistor (FET) measurement; or
(ii) the one or more characteristics of the target polynucleotide are measured by an electrical measurement, wherein the electrical measurement is a current measurement, an impedance measurement, a tunnelling measurement or a field effect transistor (FET) measurement and the method comprises:
(a) contacting the target polynucleotide with a transmembrane pore and a Dda helicase or a construct such that the helicase or the construct controls the movement of the target polynucleotide through the pore; and
(b) measuring the current passing through the pore as the polynucleotide moves with respect to the pore wherein the current is indicative of one or more characteristics of the target polynucleotide and thereby characterising the target polynucleotide; and/or
(C) the method further comprises the step of applying a voltage across the pore to form a complex between the pore and the helicase or construct; and/or
(D) at least a portion of the polynucleotide is double stranded; and/or
(E) the pore is a transmembrane protein pore or a solid state pore.

### Claim at position 33

-49. (canceled)

### Claim 50 (depends on 44)

A method according to (E) of claim 44, wherein:
(A) the transmembrane protein pore is derived from a hemolysin, leukocidin, Mycobacterium smegmatis porin A (MspA), MspB, MspC, MspD, outer membrane porin F (OmpF), outer membrane porin G (OmpG), outer membrane phospholipase A, Neisseria autotransporter lipoprotein (NalP) and WZA; or
(B) the transmembrane protein is:
(a) formed of eight identical subunits as shown in SEQ ID NO: 2 or (b) a variant thereof in which one or more of the eight subunits has at least 50% homology to SEQ ID NO: 2 based on amino acid identity over the entire sequence and retains pore activity; or
(c) α-hemolysin formed of seven identical subunits as shown in SEQ ID NO: 4 or (d) a variant thereof in which one or more of the seven subunits has at least 50% homology to SEQ ID NO: 4 based on amino acid identity over the entire sequence and retains pore activity.

### Claim 51

(canceled)

### Claim 52 (depends on 32)

A method of forming a sensor for characterising a target polynucleotide, comprising forming a complex between (a) a pore and (b) a Dda helicase or a construct according to claim 32 and thereby forming a sensor for characterising the target polynucleotide.

### Claim 53 (depends on 52)

A method according to claim 52, wherein:
(A) the complex is formed by (a) contacting the pore and the helicase or construct in the presence of the target polynucleotide and (b) applying a potential across the pore; or
(B) the complex is formed by (a) contacting the pore and the helicase or construct in the presence of the target polynucleotide and (b) applying a potential across the pore, wherein the potential is a voltage potential or a chemical potential, or the complex is formed by covalently attaching the pore to the helicase or construct.

### Claim at position 38

-55. (canceled)

### Claim 56 (depends on 32)

A sensor for characterising a target polynucleotide, comprising a complex between (a) a pore and (b) a Dda helicase or a construct according to claim 32.

### Claim 57 (depends on 32)

Use of a Dda helicase or a construct according to claim 32 to control the movement of a target polynucleotide through a pore.

### Claim 58 (depends on 32)

A kit for characterising a target polynucleotide comprising:
(A) (a) a pore and (b) a Dda helicase or a construct according to claim 32; or
(B) (a) a pore, (b) a Dda helicase or a construct according to claim 32 and (c) comprises a chip comprising a amphiphilic membrane.

### Claim 59

(canceled)

### Claim 60 (depends on 32)

An apparatus for characterising target polynucleotides in a sample, comprising (a) a plurality of pores and (b) a plurality of Dda helicases or a plurality of constructs according to claim 32.

### Claim 61 (depends on 60)

An apparatus according to claim 60, wherein the apparatus comprises:
(A) a sensor device that is capable of supporting the plurality of pores and being operable to perform polynucleotide characterisation using the pores and helicases or constructs; and
at least one port for delivery of the material for performing the characterisation; or
(B) a sensor device that is capable of supporting the plurality of pores and being operable to perform polynucleotide characterisation using the pores and helicases or constructs; and
at least one reservoir for holding material for performing the characterization; or
(C) a sensor device that is capable of supporting the plurality of pores and being operable to perform polynucleotide characterisation using the pores and helicases or constructs;
at least one reservoir for holding material for performing the characterisation;
a fluidics system configured to controllably supply material from the at least one reservoir to the sensor device; and
one or more containers for receiving respective samples, the fluidics system being configured to supply the samples selectively from one or more containers to the sensor device.

### Claim at position 45

-63. (canceled)

### Claim 64 (depends on 1)

A method of producing a helicase according to claim 1, comprising:
(A) (a) providing a Dda helicase; and
(b) modifying the helicase to produce a helicase according to claim 1; or
(B) (a) providing a Dda helicase;
(b) modifying the helicase to produce a helicase according to claim 1; and
(c) determining whether or not the resulting helicase is capable of controlling the movement of a polynucleotide; or
(C) (a) providing a Dda helicase;
(b) modifying the helicase to produce a helicase according to claim 1;
(c) determining whether or not the resulting helicase is capable of controlling the movement of a polynucleotide; and
(d) determining whether or not the resulting construct is capable of controlling the movement of a polynucleotide.

### Claim 65

(canceled)

### Claim 66 (depends on 32)

A method of producing a construct according to claim 32, comprising attaching a Dda helicase to an additional polynucleotide binding moiety and thereby producing a construct of the invention.

### Claim 67

(canceled)

### Claim 68

A Dda helicase which comprises a variant of SEQ ID NO: 8 comprising (a) A360K; (b) Y92L and/or A360Y; (c) Y92L, Y350N and Y363N; (d) Y92L and/or Y363N or (e) Y92L, wherein the helicase retains its ability to control the movement of a polynucleotide.

### Claim 69 (depends on 1)

A series of two or more helicases attached to a polynucleotide, wherein at least one of the two or more helicases is a Dda helicase according to claim 1.
